Sign in
Active, not recruitingNo phase

Observational Study in Multiple System Atrophy

Key facts

Who runs it
H. Lundbeck A/S
Where
China8 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
90 people, planned
Started
25 Jun 2022
Expected to end
30 May 2031
Type of study
Observational
Treatments tested
  • plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort
Record updated
8 December 2025

Who can take part

Age
40 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • The patient must be aged between ≥40 and ≤75 years, at baseline
  • The patient must be diagnosed with possible or probable MSA of the parkinsonian subtype (MSA-P) or cerebellar subtype (MSA-C), according to the Gilman criteria (version 2)
  • The patient must have an anticipated survival of at least 3 years in the opinion of the study investigator, at baseline
  • The patient had onset of motor MSA symptoms within 5 years prior to the baseline visit in the judgement of the study investigator
  • The patient must have an UMSARS Part I score of ≤16 (omitting question 11 on sexual function), at baseline
  • The patient must have normal cognition (i.e., Montreal Cognitive Assessment [MoCA] score ≥22), at baseline
  • The patient's caregiver must have approximately 3 hours per week contact with the patient and be available and able to accompany the patient to routine clinical visits throughout the study, to provide information on the patient's functional abilities
  • The patient/patient's legally acceptable representative, and the patient's caregiver are willing to provide written voluntary informed consent
  • The patient's treatments are prescribed according to routine clinical practice and local guidelines/regulations

Who cannot take part

  • The patient has previously been enroled in this study
  • The patient has evidence (clinical or on MRI) and/or history of any serious neurological disorder, other intracranial or systemic diseases or conditions resulting in a diagnosis other than MSA
  • The patient has two or more blood relatives with a history of MSA
  • The patient is, in the investigator's opinion, unlikely to comply with the protocol
  • The patient is a member of the study personnel or of their immediate family or is a subordinate (or immediate family member of a subordinate) to any of the study personnel

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Talisman is global clinical study (20058N) in Multiple System Atrophy (MSA) patients. It will be conducted in two regions (China and the European Union [EU]). There will be common study objectives between China and EU regions (including prospective assessments for MSA disease progression during routine clinical visits for MSA), and this will allow for data (on common objectives) to be presented overall and stratified by region. There will also be study objectives specific to each region: 1) the clinical assessment for MSA (Unified MSA Rating Scale [UMSARS]) has not been validated using standardised methods in China, and so the psychometric properties of the Chinese version of the UMSARS will be examined in Chinese patients in this study; 2) there will be retrospective assessments and prospective protocol-mandated assessments (of Magnetic Resonance Imaging [MRI] and bloods biomarkers) and study visits for EU patients.

Read full original descriptionShow less

Because some study objectives are the same for China and the EU (i.e., prospective assessments during routine clinical visits for MSA), and other objectives are specific to each region, there will be one regional protocol for China and one regional protocol for the EU; each describing the study assessments relevant to each region.

The group in the trial

  • Patients diagnosed with possible or probable MSA

    This protocol does not mandate the use of any treatments. No study medication will be administered as part of study participation. Any treatment that study patients receive will be prescribed according to the recommendations given in the local SmPCs.

    Treatment: plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
TALISMAN - Tracking Longitudinal Changes in MSA - International Natural History Study
Publications
Record updated
8 December 2025